C4 Therapeutics (CCCC) Capital Expenditures (QoQ) (2020 - 2026)
C4 Therapeutics (CCCC) Capital Expenditures (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | C4 Therapeutics | 460.17 Mn | 224.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -93.47% |
| Dec 31, 2025 | 463.75% |
| Sep 30, 2025 | -186.49% |
| Dec 31, 2024 | -102.34% |
| Sep 30, 2024 | 1,215.38% |
| Dec 31, 2023 | -73.83% |
| Sep 30, 2023 | 65.75% |
| Jun 30, 2023 | -38.54% |
| Mar 31, 2023 | -60.47% |
| Dec 31, 2022 | -54.92% |
| Sep 30, 2022 | 524.76% |
| Jun 30, 2022 | 207.56% |
| Sep 30, 2021 | -361.88% |
| Jun 30, 2021 | -38.23% |
| Mar 31, 2021 | 148.11% |
| Dec 31, 2020 | -15.65% |
| Sep 30, 2020 | 17,150.00% |
| Jun 30, 2020 | -83.33% |
| Mar 31, 2020 | -99.04% |